Century Therapeutics (IPSC) Common Equity (2020 - 2026)

Century Therapeutics (IPSC) has reported Common Equity for 7 consecutive years, with $264.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 10.11% year-over-year to $264.7 million; the TTM figure through Mar 2026 stood at $264.7 million (up 10.11% YoY), while the FY2025 annual figure was $158.9 million, down 1.5% from the prior year.
• Common Equity climbed to $264.7 million in Q1 2026 per IPSC's latest filing, from $158.9 million in the prior quarter.
• Across five years, Common Equity topped out at $386.7 million in Q1 2022 and bottomed at $158.9 million in Q4 2025.
• Historically, Common Equity has averaged $242.0 million across 5 years, with a median of $222.1 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity soared 522.32% — and 2023, when it sank 38.97%.
• Century Therapeutics' Common Equity stood at $302.7 million in 2022, then tumbled by 38.97% to $184.8 million in 2023, then declined by 12.66% to $161.4 million in 2024, then decreased by 1.5% to $158.9 million in 2025, then surged by 66.57% to $264.7 million in 2026.
• Business Quant data shows IPSC's Common Equity at $264.7 million in Q1 2026, $158.9 million in Q4 2025, and $176.3 million in Q3 2025.